Brii biosciences is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas. 腾盛博药在2025年AASLD大会上发布ENSURE II期研究最新突破性数据,进一步强调BRII-179作为慢乙肝治愈性疗法的潜力 2025年11月07日 Brii biosciences limited (“brii bio”, stock code 2137.hk) is a biotechnology company developing therapies to address major public health challenges where patients experience high unmet medical needs, limited choice and significant social stigmas.
OPEN